Norgine announced the successful completion of the acquisition of Theravia, an international pharmaceutical company specialising in therapies for patients with rare and debilitating conditions. The closure of this acquisition marks a major step forward for Norgine to deliver on its ambition to bring life-changing medicines to patients with high unmet medical needs.
With the transaction now complete, Norgine will begin a structured integration process to align operations, systems, and teams.
“We are pleased about the successful closing of this acquisition as the addition of Theravia to our company further enhances our expertise in, and growing portfolio of rare disease medicines,” said Janneke van der Kamp, Chief Executive Officer, Norgine. “This acquisition marks a critical step forward in our growth strategy, and with our strong focus on expanding the reach of products to patients in areas of high unmet medical need in Europe and ANZ, we are well positioned to ensure Theravia’s medicines will reach more patients.”
Health Technology Insights: Rhapsody Launches Image Director to Streamline Imaging Workflows
To participate in our interviews, please write to our HealthTech Media Room at sudipto@dmintentamplify-com
Source- PR Newswire
